

Communication

MDPI

A Survey of Recent Adenoviral Respiratory Pathogens in Hong Kong Reveals Emergent and Recombinant Human Adenovirus Type 4 (HAdV-E4) Circulating in Civilian Populations

Jing Zhang ¹, June Kang ², Shoaleh Dehghan ^{2,3}, Siddharth Sridhar ⁴, Susanna K. P. Lau ⁴, Junxian Ou ¹, Patrick C. Y. Woo ⁴, Qiwei Zhang ^{1,5,*} and Donald Seto ^{2,*}

- ¹ Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, Guangdong, China; 243562394@smu.edu.cn (J.Z.); ojx426@smu.edu.cn (J.O.)
- ² Bioinformatics and Computational Biology Program, School of Systems Biology, George Mason University, Manassas, VA 20110, USA; qkang@masonlive.gmu.edu (J.K.); shoalehd@gmail.com (S.D.)
- ³ Chemistry Department, American University, Washington, DC 20016, USA
- ⁴ Department of Microbiology, The University of Hong Kong, Hong Kong, China; sid8998@hku.hk (S.S.); skplau@hku.hk (S.K.P.L.); pcywoo@hku.hk (P.C.Y.W.)
- ⁵ Guangzhou Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China
- * Correspondence: zhangqw@smu.edu.cn (Q.Z.); dseto@gmu.edu (D.S.); Tel.: +86-20-6164-8649 (Q.Z.); +1-703-993-8403 (D.S.)

Received: 18 January 2019; Accepted: 30 January 2019; Published: 31 January 2019



Abstract: Human adenovirus type 4 (HAdV-E4), which is intriguingly limited to military populations, causes acute respiratory disease with demonstrated morbidity and mortality implications. This respiratory pathogen contains genome identity with chimpanzee adenoviruses, indicating zoonotic origins. A signature of these "old" HAdV-E4 is the absence of a critical replication motif, NF-I, which is found in all HAdV respiratory pathogens and most HAdVs. However, our recent survey of flu-like disease in children in Hong Kong reveals that the emergent HAdV-E4 pathogens circulating in civilian populations contain NF-I, indicating recombination and reflecting host-adaptation that enables the "new" HAdV-E4 to replicate more efficiently in human cells and foretells more potential HAdV-E4 outbreaks in immune-naïve civilian populations. Special attention should be paid by clinicians to this emergent and recombinant HAdV-E4 circulating in civilian populations.

Keywords: zoonosis; host adaptation; evolution; genome recombination; respiratory pathogens; civilian populations; human adenovirus type 4

1. Introduction

An increase in pediatric patients with influenza-like symptoms in Queen Mary Hospital (July to October 2014) led to a question as to whether the putatively host-adapted human adenovirus type 4 (HAdV-E4) [1] is circulating in Hong Kong. HAdV-E4 was one of the first viral respiratory pathogens to be isolated ("**R**(*espiratory*)**I**(*nfection*)-(*number*)**67**"; 1952) [2]. It is intriguingly extraordinary in several aspects, the first being that it is one of only two adenoviruses for which a vaccine was developed, thrice (1956, 1971, and 2011), at considerable effort and expense, attesting to its potency (https://www.historyofvaccines.org/content/blog/adenovirus-vaccines-reinstated-after-long-absence) [3]. Each vaccine cessation resulted in immediate reemergence as a major pathogen [4]. Second, HAdV-E4 was typically and inexplicably restricted to U.S. military populations [3,5,6], with occasional yet limited

infections tallied in pathogen surveys of civilian populations [5–7]. Third, taxonomically, HAdV-E4 differed from other HAdVs with respect to protein chemistry properties [8] and low-resolution genomics data, including partial sequences and restriction enzyme maps [9]. Its classification, with genome sequence, as the sole HAdV comprising clade or "species" E, with 14 simian adenoviruses (SAdVs), adds to its mystique [1,10]. Origins included speculations of being the archetypical HAdV [9] or a HAdV species B and C recombinant. Genome analysis showed RI-67 was a chimpanzee adenovirus (ChAdV) [1,10], with a genome identity of 89.8% and 89.2% to SAdV-E26 and SAdV-E25, respectively. These are much higher than two respiratory pathogens HAdV-B7 at 73.7% and HAdV-C1 at 65.7%, with ocular pathogen HAdV-D9 at 70.4%.

The zoonotic threat potential of adenoviruses is recognized [11], and HAdV-E4 represents the first example. Notably, both the HAdV-E4 prototype and contemporaneous "vaccine" isolates contain a genome signature that is unique to ChAdVs and other SAdVs, i.e., the absence of the Nuclear Factor I (NF-I) binding site that is conserved among the three replication motifs embedded in nearly all HAdV inverted terminal repeats (ITRs) [1]. NF-I is a host transcription factor that binds to nt 23–36 of the HAdV-2 origin of replication [12–20] and is recruited by the human adenoviral replication complex [12,17]. It is firmly established as essential through in vitro and in vivo studies (see [18,19] and *qtd. in*), including replication reconstitution assays, as necessary for efficient adenoviral replication motif [1], presumably permitting an expansion of the virus range into the immune-naïve populations [5–7,21–23], and should be noted as a molecular evolution example of a post-zoonotic, host-adaptation of a "novel" and "emergent" human pathogen.

2. Results and Discussion

As noted in the literature, the ITR contains critical conserved DNA replication motifs that include the human transcription factor binding site, NF-I, which is shown to enhance and optimize HAdV replication and growth [2,12–20]. All of the 10 Hong Kong isolates (red) possess this host-adapted ITR, i.e., they have the NF-I binding site that is found in all human respiratory adenoviruses (yellow) (Figure 1). However, this motif is missing in SAdV ITRs (purple) [18], as well as the "old" HAdV-E4 strains (green), e.g., prototype (1952) and "vaccine" (1962) strains, i.e., they have only the core origin and the NF-III motif [1]. The absence of the NF-I motif likely plays a role in limiting the circulation of both SAdVs and prototype HAdV-E4 in human populations, as its acquisition presumably provides efficient and enhanced replication in human cells, i.e., allowed HAdV-E4 to adapt to the new host. This may be the "tipping point" that allows HAdV-E4 entry into the general population that is immunologically-naïve to its epsilon antigen, as HAdV-E4 does not normally circulate outside the U.S. military populations [3,5–7]. This is consistent with reports documenting recombination as an evolution mechanism in the genesis of emergent HAdV pathogens [24], illustrated by HAdV-D53 [25] and HAdV-B55 [24]. HAdV-B55 is a recent major respiratory pathogen in China, after years of quiescence, by virtue of its introduction into immunologically-naïve populations, i.e., without antibodies to its HAdV-B11-like epsilon antigen. Another example is the reemergence of a long-dormant respiratory pathogen HAdV-B14 into an immunologically-naïve population [26].

Consistent with this report, recombination has been reported in SAdVs [27,28] and cross-species transmissions between humans and non-human simians have been reported [28–34], including TMAdV across "two passages" of human hosts, with clinical manifestations [34], as well as seroprevalence of adenoviruses across species [29,32–34]. These support the hypothesis and data suggesting HAdV-E4 was of zoonotic origins [1,10].

		CORE ORIGIN		NF-I	NF-III	
AdV-E4 KX384956 V0014/France/1978	- CATCATC-	A- ATAATATACC	TTATAGA	T GGAATG- GTGCCAA	TATGTAAATGA	A G G T G A T T T A A A A A G T G C G C G C T G T G T G G T G A T T G G C C G T G G A G T A A A T G G C T A A A A G G G G
AdV-B21 AC 000010	C		· · · A · CT	TTGG C TT	с	C
AdV-E25 AF394196 Pan 9 CV68	c		- C · A · CT	· TTTG· · C· C· TT· ·	c	
AdV-E22 AY530876 ATCC VR-591			· C· A· CT	TTGG C C CTT	c	
AdV-E23 AY530877 ATCC VR-592			· C· A· CT	TTGG C C TT ··	c	C
AdV-E24 AY530878 ATCC VR-593			C A CT	TTGG C C TT	c	C
AdV-E26 FJ025923			· C· A· CT	TTTG C C TT	c	- C G - TTT- G- GAG- AA- G - T T- C GAAGGGC - A- CGTT
AdV-E4p AY594253 RI-67/USA/1952	CT · · · T	т. т		TTTG T A TT	C A .	
AdV-E4 AY594254 vaccine/USA				TTTG T A TT		
AdV-E4 MF002043 RU2533/New Jersey/1966			TTT	TTTG T A TT	C	C GA TIT G GAT GG C C C ACAGCGGC TICGIT
AdV-E4 KX384948 RDU2954/New Jersey/USA/1966			· · · · TTT	- TTTG T- A- TT	C A .	
AdV-E4 KX384947 RU4445/Egypt/1968				- TTTG T- A- TT	A.	
AdV-E4 KX384950 RU7872/Minnesota/USA/1971				TTTG T A TT	A.	C. GA TIT G GAT GG C C C
AdV-E4 KX384957 V1003/New York/USA/1981				TT.G. T.A.TT.	A.	C . G . TIT G GAT GG C C C
AdV-E4 KX384946 V2029E/Georgia/USA/1986			· · · · TTT	TT-G-T-A-TT-	C A .	
AdV-E4 EF371058 NHRC90339/USA/2001				· TT. G. · T. A. TT. ·		- C - G - TIT C CAT CC C C C - T - ACACCOC TICOT
AdV-E4 KY996447 4054/USA/2015	CT T	г. т	TTT	· TTTG· · T· A· TT· ·	A.	- C - GA - TIT - G - GAT - GG - C - C - C - T - ACAGCGGC - TICGTT
AdV-E4 KY996452 J1007/Japan/1981	G					
AdV-E4 KX384955 V1933/New Mexico/USA/1985						
AdV-E4 KX384951 ZG/Indio California/USA/1995						
AdV-E4 FtJackson South Carolina/USA/1997/1998/2001/2002/2003						
AdV-F4 AV599837 NHRC3/Brooks AFB Texas/USA/2002		1				
AdV-E4 KF006344 GZ01/China/2008		-				
AdV-E4 KY996453 TB071911/USA/2011						
AdV-E4 New York isolates/USA/2012/2013/2014/2015						
AdV-F4 NVII isolates/USA/2016						
AdV-E4 HK isolates/2014						
AdV-B3 AY599834 GB/USA	CTT	т			c	A
AdV-B7 AV594255 Gomen/USA	CT T				~	
AdV-B14 AV803294 dr Wit ATCC VR-1091/USA					Č.	
AdV-B16 AY601636 cb.79/USA		т			c	G
AdV-B21 AY601633 AV-1645/USA	CT	т				X T C G G C
AdV:B50 AV737798 Wen ATCC VR:1502/USA		T			U.S.	
AdV-B11 AV163756 Slobitski/USA		1 '				
AdV-B34 AV737797 Compton/USA						T T T C C C
AdV-B35 AV128640 Holden/USA						
AdV-B55 EJ643676 OS-DLL/China/2006						т то т с т с
AUX 412 AC 000005 Ibuild IV	CCT			6.1		A GOOT OTOTOTAATTTOA TO GA OT GOT TOOC TOOTTOTAA
AUVILLAC OCOUSTIBLE ON					1 A T.	
44/ D10 10226200 USA/1005			CC. C. A.	GTA CAAAA. TT	A 1	C
441 D40 F11 (2860 Hard Finler 2002)		1		AC A	47	
AUV-040 KU 102009 HOWLAFHIND 1979			AAC	AC- A	A1	CO. C. CAGO, CONC. C. A. C. C. T. C. T.
107-032 DQ223122 103-224+COSA		Law and the second	$p \rightarrow A + A \in A \in A$	CONTRACTOR CONTRACTOR	process and services of	- co. oroxoo. ocoxo oocc. o

Figure 1. Human adenovirus Inverted Terminal Repeats (116–209 bases) embed replication proteinbinding motifs within 88 bases: "Core origin", NF-I (Nuclear Factor I), and NF-III. Host transcription factors NF-I and NF-III enable adenovirus replication in human cells. The first recorded host-adapted HAdV-E4 (Human adenovirus type 4) ITR (inverted terminal repeats) is arrayed along the top (V0014/France/1978), contrasted against differences in motifs from SAdVs (simian adenoviruses) (lavender) and prototype-like HAdV-E4 (green). Dots indicate conserved bases. Recent host-adapted HAdV-E4 isolates (blue), including five isolates from Ft. Jackson, spanning six years, and 10 recent Hong Kong isolates (red) contain these motifs and are nearly indistinguishable from motifs from HAdV respiratory pathogens (yellow). The majority of HAdVs possess these motifs (black), with the most divergent being HAdV-D19.

Since sequences diverge considerably downstream of the NF-III motif, a phylogenetic analysis of the full ITR (116–209 bases) was completed (Figure 2). Recent host-adapted "new" HAdV-E4 isolates, including Hong Kong isolates, subclade with human respiratory adenoviruses of species B as well as with other HAdVs. Prototype-like HAdV-E4 isolates subclade with SAdVs.



Figure 2. Phylogeny of select HAdV and SAdV ITRs. Recent host-adapted HAdV-E4, including Hong Kong isolates, subclade with HAdVs. Prototype-like HAdV-E4 isolates subclade with SAdVs. Inverted terminal repeats (ca., 116 bases) were aligned using Molecular Evolutionary Genetics Analysis (MEGA) 7.0.26 software (https://www.megasoftware.net), and phylogenetic trees were constructed with a maximum-likelihood method incorporating 1000 bootstrap replications.

Comparison of HAdV-E4 genomes spanning 65 years reveals highly conserved sequences. For example, the two earliest genomes, isolated within 10 years, are 99.9% identical to each other, differing by 18 mismatches and two insertions (one one-base and one three-base) [35]. One striking difference is a recombination resulting in recent HAdV-E4 genomes acquiring a well-characterized replication-enhancing NF-I motif that distinguishes these isolates from the 1952 prototype and a contemporaneous 1965 co-circulating strain. Although the acquisition of this critical replication motif alone may explain the potentially wider distribution of HAdV-E4, the pair-wise sequence analyses also reveal additional potentially important sequence differences in the E3 gene region [36]. Proteins encoded in the E3 region are involved in interactions with the host immune response and evasion and represent the most variable region between HAdV types [37–39]. This report highlights the need to re-explore the understudied E3 genes and their critical roles in the human immune response upon HAdV infection.

However, whether in concert with E3 gene changes or alone, the NF-I acquisition, given "Occam's Razor", may be the critical evolutionary modification and "tipping point" that is necessary for a wider distribution of HAdV-E4 in immune-naïve civilian populations in light of the extensive literature reported for HAdV replication requirements [12–20]. This host adaptation may be significant as HAdV-E4 is a highly contagious pathogen with demonstrated morbidity and mortality implications and has now been reported in global civilian populations [6,7,23]. During the preparation of this report, to emphasize further the potential of HAdV-E4 emergence in the global general population, seroepidemiological data identifying HAdV-E4 infections in China and Sierra Leone (Africa) were published [40]. Explicitly, the authors note "An apparent increase in the frequency of human adenovirus type 4 (HAdV-4) infections among general populations has been observed over the past 10 years" [40].

3. Materials and Methods

3.1. Clinical Specimens and Virus Culture

Nasopharyngeal swab specimens were collected from both outpatients and inpatients who presented with flu-like symptoms, and are archived at Queen Mary Hospital (Hong Kong). Adenoviruses were detected by PCR and were identified further by molecular typing using partial sequence data from the hexon and fiber genes, as previously reported [41]. Then, 10 virus strains that were identified as type 4 were cultured in human lung cell lines (A549), and genomic DNA was extracted using the Viral DNA Extraction Kit from Omega Bio-Tek, Inc. (Norcross, GA, USA), as previously noted [41].

3.2. DNA Sequencing and Bioinformatic Analyses

ITRs were sequenced using genomic DNA as a template, with either a 5'-primer "Ad4-ITR-L" (5'-AACTCTTCTCGCTGGCACTCAA-3') or a 3'-primer "Ad4-ITR-R" (5'-CCGCCCCTAACAGTCGCC-3'). These Sanger chemistry-derived ITR sequence data generated with an ABI3730 DNA sequencer were aligned and parsed for sequence motifs. Phylogenetic analysis was undertaken with Molecular Evolutionary Genetics Analysis software (MEGA) 7.0.26 (https://www.megasoftware.net), for which FASTA files were inputted for sequence alignments utilizing a Maximum Composite Likelihood method to generate neighbor-joining, bootstrapped phylogenetic trees with 1000 iterations [1,42]. All other MEGA program parameters were set by default. Bootstrap values above 80 are considered robust. For pair-wise genome comparisons, zPicture (http://zpicture.dcode.org/) was used to provide detailed global insights.

3.3. Sequence Data

All sequences are available in GenBank from which whole genome data were retrieved and aligned, and ITR sequences extracted. This resulted in a data set of ITR sequences ranging from 116 to 209 bases, as lengths were variable among the types. A subset of sequences spanning the first

1–66 bases that included the conserved HAdV viral replication sequence motifs were selected for detailed analysis.

Genome sequence data were accessed from GenBank. HAdV-E4 genomes include RI-67 or "prototype" (Ft Leonard Wood, Missouri; 1952; AY594253); CL68578 or "vaccine" (Camp Lejeune, North Carolina; 1965; AY487947); V0014 (France; 1978; KX384956); JAX78 (Ft Jackson, South Carolina; 1997; KX384953); and NHRC3 (Brooks AFB, Texas; 2002; AY599837); NVI771 (USA; 2016; MG030484); NVI692 (USA; 2016; MG030485); NVI727 (USA; 2016; MG030483); 1418 (New York; 2015; MF002042); 3477 (USA; 2015; KY996446); 33430 (USA; 2014; KY996445); 38813 (New York; 2014; KY996444); 38662 (USA; 2014; KY996443); 4876 (USA; 2014; KY996448); 9111 (USA; 2014; KY996442); 5497 (USA; 2013; KY996449); 27440 (USA; 2012; KY996451); 12752 (USA; 2012; KY996450); TB071911 (USA; 2011; KY996453); GZ01 (China; 2008; KF006344); NHRC42606 (Ft Jackson, South Carolina; 2003; AY599835); T158 (Ft Jackson, South Carolina; 2002; KX384945); 10 (Ft Jackson, South Carolina; 2001; KX384954); 186 (Ft Jackson, South Carolina; 1998; KX384952); 078 (Ft Jackson, South Carolina; 1997; KX384953); ZG (Indio, California; 1995; KX384951); V1933 (New Mexico; 1985; KX384955); J1007; Japan; 1981; KY996452); NVI1694 (USA; 2016; MG030486); NHRC90339 (USCG Training Ctr (Cape May), Delaware; EF371058); V1003 (New York; 1981; KX384957); V2029E (Georgia; 1986; KX384946); RU2533 (New Jersey; 1966; MF002043); RDU2954 (New Jersey; 1966; KX384948); RU4445 (Egypt; 1968; KX384947); RU7872 (Minnesota; 1971; KX384950); and 4054 (USA; 2015; KY996447). Additional representative HAdV genomes include HAdV-B50 (Wan; AY737798); HAdV-B16 (ch.79; AY601636); HAdV-B3 (GB; AY599834); HAdV-B7 (Gomen; AY594255); HAdV-B14 (de Wit; AY803294); HAdV-B55 (QS-DL; FJ643676); HAdV-B11 (Slobitski; AY163756); HAdV-B34 (Compton; AY737797); HAdV-B35 (Holden; AY128640); HAdV-B21 (AV-1645; AY601633); HAdV-A12 (Huie; AC 000005); HAdV-F40 (HowiX; FH162869); HAdV-G52 (T03-2244; DQ923122); HAdV-C1 (AF534906); HAdV-C2 (AC_000007); HAdV-C5 (7151; AY601635); HAdV-C6 (Tonsil 99; FJ349096); HAdV-D9 (Hicks; AJ854486); HAdV-D37 (GW76-19026; DQ900900); HAdV-D19 (JQ326209); and HAdV-D17 (AF108105). Simian adenoviral genomes include SAdV-B21 (AC_000010); SAdV-E22 (AY530876); SAdV-E23 (AY530877); SAdV-E24 (AY530878); SAdV-E25 (AF394196); and SAdV-E26 (FJ025923). The ITR sequences of Hong Kong HAdV-E4 isolates are archived in GenBank (KY062614-KY062623).

Author Contributions: Q.Z. and D.S. conceived of this project, as well as designed and analyzed the data, and prepared the manuscript. J.Z., J.O., J.K., and S.D. performed the analyses, analyzed the data, and contributed to the manuscript; S.S., S.K.P.L., and P.C.Y.W provided specimens and clinical metadata.

Funding: This work was supported by the National Natural Science Foundation of China (31570155, 31370199) and Guangzhou Healthcare Collaborative Innovation Major Project (201803040004, 201803040007).

Acknowledgments: D.S. thanks Q.Z. and the Southern Medical University for an appointment as Visiting Professor, and also K.Y. Yuen (Hong Kong University) for the lecture invitation that initiated this collaboration. D.S. is grateful to Harold Suarez del Toro and the staff, particularly Margarito Ricardez de la Cruz, of the Biwa Hotel in Tulum (Mexico) for providing a warm, tranquil, and hospitable environment that was conducive for a writing sabbatical in Winter 2018-19.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Dehghan, S.; Seto, J.; Liu, E.B.; Walsh, M.P.; Dyer, D.W.; Chodosh, J.; Seto, D. Computational analysis of four human adenovirus type 4 genomes reveals molecular evolution through two interspecies recombination events. *Virology* 2013, 443, 197–207. [CrossRef] [PubMed]
- 2. Hilleman, M.R.; Werner, J.H. Recovery of new agent from patients with acute respiratory illness. Proceedings of the Society for Experimental Biology and Medicine. *Exp. Biol. Med.* **1954**, *85*, 183–188. [CrossRef]
- 3. Potter, R.N.; Cantrell, J.A.; Mallak, C.T.; Gaydos, J.C. Adenovirus-associated deaths in US military during postvaccination period, 1999–2010. *Emerg. Infect. Dis.* **2012**, *18*, 507–509. [CrossRef] [PubMed]
- 4. Barraza, E.M.; Ludwig, S.L.; Gaydos, J.C.; Brundage, J.F. Reemergence of adenovirus type 4 acute respiratory disease in military trainees: Report of an outbreak during a lapse in vaccination. *J. Infect. Dis.* **1999**, *179*, 1531–1533. [CrossRef] [PubMed]

- Kajon, A.E.; Moseley, J.M.; Metzgar, D.; Huong, H.S.; Wadleigh, A.; Ryan, M.A.; Russell, K.L. Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997–2003). *J. Infect. Dis.* 2007, 196, 67–75. [CrossRef] [PubMed]
- Kajon, A.E.; Lamson, D.M.; Bair, C.R.; Lu, X.Y.; Landry, M.L.; Menegus, M.; Erdman, D.D.; St George, K. Adenovirus type 4 respiratory infections among civilian adults, Northeastern United States, 2011–2015. *Emerg. Infect. Dis.* 2018, 24, 201–209. [CrossRef] [PubMed]
- Hang, J.; Vento, T.J.; Norby, E.A.; Jarman, R.G.; Keiser, P.B.; Kuschner, R.A.; Binn, L.N. Adenovirus type 4 respiratory infections with a concurrent outbreak of coxsackievirus A21 among United States army basic trainees, a retrospective viral etiology study using next-generation sequencing. *J. Med. Virol.* 2017, 89, 1387–1394. [CrossRef] [PubMed]
- 8. Wadell, G. Classification of human adenoviruses by SDS-polyacrylamide gel electrophoresis of structural polypeptides. *Intervirology* **1979**, *11*, 47–57. [CrossRef] [PubMed]
- 9. Li, Q.G.; Wadell, G. The degree of genetic variability among adenovirus type 4 strains isolated from man and chimpanzee. *Arch. Virol.* **1988**, *101*, 65–77. [CrossRef]
- 10. Purkayastha, A.; Ditty, S.E.; Su, J.; McGraw, J.; Hadfield, T.L.; Tibbetts, C.; Seto, D. Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: Implications for gene therapy and vaccine vector development. *J. Virol.* **2005**, *79*, 2559–2572. [CrossRef]
- 11. Bailey, E.S.; Fieldhouse, J.K.; Choi, J.Y.; Gray, G.C. A mini review of the zoonotic threat potential of influenza viruses, coronaviruses, adenoviruses, and enteroviruses. *Front. Public Health* **2018**, *6*, 104. [CrossRef] [PubMed]
- 12. Nagata, K.; Guggenheimer, R.A.; Hurwitz, J. Specific binding of a cellular DNA replication protein to the origin of replication of adenovirus DNA. *Proc. Natl. Acad. Sci. USA* **1983**, *80*, 6177–6181. [CrossRef] [PubMed]
- 13. Rawlins, D.R.; Rosenfeld, P.J.; Wides, R.J.; Challberg, M.D.; Kelly, T.J., Jr. Structure and function of the adenovirus origin of replication. *Cell* **1984**, *37*, 309–319. [CrossRef]
- 14. Diffley, J.F.; Stillman, B. Purification of a cellular, double-stranded DNA-binding protein required for initiation of adenovirus DNA replication by using a rapid filter-binding assay. *Mol. Cell. Biol.* **1986**, *6*, 1363–1373. [CrossRef] [PubMed]
- 15. Rosenfeld, P.J.; Kelly, T.J. Purification of nuclear factor I by DNA recognition site affinity chromatography. *J. Biol. Chem.* **1986**, *261*, 1398–1408. [PubMed]
- De Vries, E.; van Driel, W.; van den Heuvel, S.J.; van der Vliet, P.C. Contactpoint analysis of the hela nuclear factor i recognition site reveals symmetrical binding at one side of the DNA helix. *EMBO J.* 1987, *6*, 161–168. [CrossRef] [PubMed]
- 17. Kenny, M.K.; Balogh, L.A.; Hurwitz, J. Initiation of adenovirus DNA replication. I. Mechanism of action of a host protein required for replication of adenovirus DNA templates devoid of the terminal protein. *J. Biol. Chem.* **1988**, *263*, 9801–9808. [PubMed]
- Hatfield, L.; Hearing, P. Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for virus growth in vivo. *Virology* 1991, 184, 265–276. [CrossRef]
- Mul, Y.M.; Verrijzer, C.P.; van der Vliet, P.C. Transcription factors nfi and nfiii/oct-1 function independently, employing different mechanisms to enhance adenovirus DNA replication. *J. Virol.* 1990, 64, 5510–5518. [PubMed]
- 20. Stillman, B.W.; Topp, W.C.; Engler, J.A. Conserved sequences at the origin of adenovirus DNA replication. *J. Virol.* **1982**, *44*, 530–537.
- 21. Kandel, R.; Srinivasan, A.; D'Agata, E.M.; Lu, X.; Erdman, D.; Jhung, M. Outbreak of adenovirus type 4 infection in a long-term care facility for the elderly. *Infect. Cont. Hosp. Epidemiol.* **2010**, *31*, 755–757. [CrossRef] [PubMed]
- 22. Chen, H.L.; Chiou, S.S.; Hsiao, H.P.; Ke, G.M.; Lin, Y.C.; Lin, K.H.; Jong, Y.J. Respiratory adenoviral infections in children: A study of hospitalized cases in southern Taiwan in 2001–2002. *J. Trop. Pediatr.* **2004**, *50*, 279–284. [CrossRef] [PubMed]
- 23. Li, J.; Lu, X.; Sun, Y.; Lin, C.; Li, F.; Yang, Y.; Liang, Z.; Jia, L.; Chen, L.; Jiang, B.; et al. A swimming pool-associated outbreak of pharyngoconjunctival fever caused by human adenovirus type 4 in Beijing, China. *Int. J. Infect. Dis.* **2018**, *75*, 89–91. [CrossRef]

- 24. Walsh, M.P.; Seto, J.; Jones, M.S.; Chodosh, J.; Xu, W.; Seto, D. Computational analysis identifies human adenovirus type 55 as a re-emergent acute respiratory disease pathogen. *J. Clin. Microbiol.* **2010**, *48*, 991–993. [CrossRef] [PubMed]
- Walsh, M.P.; Chintakuntlawar, A.; Robinson, C.M.; Madisch, I.; Harrach, B.; Hudson, N.R.; Schnurr, D.; Heim, A.; Chodosh, J.; Seto, D.; et al. Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis. *PLoS ONE* 2009, *4*, e5635. [CrossRef]
- Carr, M.J.; Kajon, A.E.; Lu, X.; Dunford, L.; O'Reilly, P.; Holder, P.; De Gascun, C.F.; Coughlan, S.; Connell, J.; Erdman, D.D.; et al. Deaths associated with human adenovirus-14p1 infections, Europe, 2009–2010. *Emerg. Infect. Dis.* 2011, 17, 1402–1408. [CrossRef] [PubMed]
- Hoppe, E.; Pauly, M.; Robbins, M.; Gray, M.; Kujirakwinja, D.; Nishuli, R.; Boji Mungu-Akonkwa, D.D.; Leendertz, F.H.; Ehlers, B. Phylogenomic evidence for recombination of adenoviruses in wild gorillas. *J. Gen. Virol.* 2015, *96*, 3090–3098. [CrossRef]
- 28. Dehghan, S.; Seto, J.; Jones, M.S.; Dyer, D.W.; Chodosh, J.; Seto, D. Simian adenovirus type 35 has a recombinant genome comprising human and simian adenovirus sequences, which predicts its potential emergence as a human respiratory pathogen. *Virology* **2013**, *447*, 265–273. [CrossRef]
- 29. Pauly, M.; Akoua-Koffi, C.; Buchwald, N.; Schubert, G.; Weiss, S.; Couacy-Hymann, E.; Anoh, A.E.; Mossoun, A.; Calvignac-Spencer, S.; Leendertz, S.A.; et al. Adenovirus in rural cote d'ivoire: High diversity and cross-species detection. *Ecohealth* **2015**, *12*, 441–452. [CrossRef]
- Hoppe, E.; Pauly, M.; Gillespie, T.R.; Akoua-Koffi, C.; Hohmann, G.; Fruth, B.; Karhemere, S.; Madinda, N.F.; Mugisha, L.; Muyembe, J.J.; et al. Multiple cross-species transmission events of human adenoviruses (HAdV) during hominine evolution. *Mol. Biol. Evol.* 2015, *32*, 2072–2084. [CrossRef]
- 31. Wevers, D.; Metzger, S.; Babweteera, F.; Bieberbach, M.; Boesch, C.; Cameron, K.; Couacy-Hymann, E.; Cranfield, M.; Gray, M.; Harris, L.A.; et al. Novel adenoviruses in wild primates: A high level of genetic diversity and evidence of zoonotic transmissions. *J. Virol.* **2011**, *85*, 10774–10784. [CrossRef] [PubMed]
- 32. Chiu, C.Y.; Yagi, S.; Lu, X.; Yu, G.; Chen, E.C.; Liu, M.; Dick, E.J., Jr.; Carey, K.D.; Erdman, D.D.; Leland, M.M.; et al. A novel adenovirus species associated with an acute respiratory outbreak in a baboon colony and evidence of coincident human infection. *mBio* **2013**, *4*, e00084. [CrossRef] [PubMed]
- Ersching, J.; Hernandez, M.I.; Cezarotto, F.S.; Ferreira, J.D.; Martins, A.B.; Switzer, W.M.; Xiang, Z.; Ertl, H.C.; Zanetti, C.R.; Pinto, A.R. Neutralizing antibodies to human and simian adenoviruses in humans and new-world monkeys. *Virology* 2010, 407, 1–6. [CrossRef] [PubMed]
- 34. Chen, E.C.; Yagi, S.; Kelly, K.R.; Mendoza, S.P.; Tarara, R.P.; Canfield, D.R.; Maninger, N.; Rosenthal, A.; Spinner, A.; Bales, K.L.; et al. Cross-species transmission of a novel adenovirus associated with a fulminant pneumonia outbreak in a new world monkey colony. *PLoS Pathog.* **2011**, *7*, e1002155. [CrossRef]
- 35. Purkayastha, A.; Su, J.; McGraw, J.; Ditty, S.E.; Hadfield, T.L.; Seto, J.; Russell, K.L.; Tibbetts, C.; Seto, D. Genomic and bioinformatics analyses of HAdV-4vac and HAdV-7vac, two human adenovirus (HAdV) strains that constituted original prophylaxis against HAdV-related acute respiratory disease, a reemerging epidemic disease. *J. Clin. Microbiol.* **2005**, *43*, 3083–3094. [CrossRef] [PubMed]
- 36. Seto, D. Phylogenetic analysis of circulating HAdV-E4 strains. 2019; in preparation.
- 37. Singh, G.; Robinson, C.M.; Dehghan, S.; Schmidt, T.; Seto, D.; Jones, M.S.; Dyer, D.W.; Chodosh, J. Overreliance on the hexon gene, leading to misclassification of human adenoviruses. *J. Virol.* **2012**, *86*, 4693–4695. [CrossRef]
- Benedict, C.A.; Norris, P.S.; Prigozy, T.I.; Bodmer, J.L.; Mahr, J.A.; Garnett, C.T.; Martinon, F.; Tschopp, J.; Gooding, L.R.; Ware, C.F. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. *J. Biol. Chem.* 2001, 276, 3270–3278. [CrossRef]
- 39. Lichtenstein, D.L.; Toth, K.; Doronin, K.; Tollefson, A.E.; Wold, W.S.M. Functions and mechanisms of action of the adenovirus E3 proteins. *Int. Rev. Immunol.* **2004**, *23*, 75–111. [CrossRef]
- 40. Wang, B.; Li, J.; Wu, S.; Chen, Y.; Zhang, Z.; Zhai, Y.; Guo, Q.; Zhang, J.; Song, X.; Zhao, Z.; et al. Seroepidemiological investigation of hadv-4 infection among healthy adults in china and in Sierra Leone, West Africa. *Emerg. Microbes Infect.* **2018**, *7*, 200. [CrossRef]

- 41. Han, G.; Niu, H.; Zhao, S.; Zhu, B.; Wang, C.; Liu, Y.; Zhang, M.; Yang, S.; Liu, F.; Wan, C.; et al. Identification and typing of respiratory adenoviruses in Guangzhou, southern China using a rapid and simple method. *Virol. Sin.* **2013**, *28*, 103–108. [CrossRef]
- 42. Kumar, S.; Stecher, G.; Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. *Mol. Biol. Evol.* **2016**, *33*, 1870–1874. [CrossRef] [PubMed]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).